Navigation Links
Kendle Rated a Top CRO to Work with for Fourth Consecutive Year
Date:6/3/2010

CINCINNATI, June 3 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced it is ranked a top CRO to work with in the 2010 CenterWatch European Investigative Site Survey. Kendle is the only CRO to be ranked consistently among the top three providers for each of the past four years in the annual U.S. and European site surveys conducted by CenterWatch, a leading publishing and information services company focusing on the clinical trials industry. In the 2010 survey of investigative sites across 30 European countries Kendle was rated a top-three CRO on 21 of the 29 individual survey attributes and in particular ranked highly in the study initiation category, receiving the highest percentage of "excellent" ratings for its protocol design (48.5 percent) and for protocols aligning scientific rationale with clinical practice realities (50 percent).

"Kendle's ability to forge strong and collaborative relationships with investigative sites across the globe is key to our ability to deliver studies more efficiently and cost effectively for our customers, which is increasingly important in today's environment," said Stephen Cutler, PhD, Senior Vice President and Chief Operating Officer. "Our continued recognition as a top-rated CRO and the fact that we are the only CRO to have been ranked consistently among the top three providers since 2007 is a further testament to our ability to build long-lasting and successful site relationships in support of our customers' needs."

In the 2010 European Investigative Site Survey, 76.1 percent of sites rated Kendle "Good" or "Excellent" for overall relationship quality. In addition to excelling in the study initiation category Kendle also scored highly on the ongoing study conduct and grant payment performance attributes. In an article detailing the survey results in the June 2010 issue of The CenterWatch Monthly, CenterWatch notes "Kendle has stayed true to their word of continuous improvement from previous years— actively listening to the needs of investigative sites, implementing change when needed—and generally adopting a proactive strategy to strengthen their relationships with sites."

CenterWatch conducted the survey of investigative sites across Europe between January and March 2010. The biennial survey, which has been conducted since 1997 in both North America and Europe, was developed with input from clinical research professionals at sponsor companies, CROs and investigative sites. A total of 924 investigative sites completed the survey, which evaluated the performance of CROs across 29 specific relationship attributes relating to general project management, personnel and work-style and project-specific areas. In addition, sites also provided feedback on the importance of these attributes when conducting their clinical trials.

Kendle's rating as a top CRO in the 2010 European Investigative Site Survey follows its strong performance in the annual CenterWatch investigative site surveys during each of the past four years. In the 2009 CenterWatch survey of U.S. investigative sites Kendle ranked second with 72 percent of sites surveyed rating the Company as "Good" or "Excellent." Kendle also ranked second in the 2008 CenterWatch Survey of European Investigative Sites and ranked first overall in the 2007 CenterWatch Survey of U.S. Investigative Sites.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Announces New Revolving Credit Facility
2. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
3. Kendle to Present at UBS Global Life Sciences Conference
4. Kendle to Present at Robert Baird 2009 Health Care Conference
5. Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
6. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
7. Kendle Names Jarrod Pontius Chief Legal Officer
8. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
9. Kendle Announces First Quarter 2009 Results
10. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
11. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):